In early breast cancer, the molecular detection of cytokeratin 19 (CK-19) mRNA-positive cells in peripheral blood before [24], during [25], and after adjuvant therapy [26] is associated with worse prognosis, while their elimination seems to be an efficacy indicator of treatment [27]. This evidence concerns the gene KRT19 and breast cancer.